Egyptian trial to test semaglutide before surgery at BMI 60 and above
The phase 4 randomized, double-blind, placebo-controlled study targets a group almost never recruited, measuring surgical feasibility and safety rather than weight loss alone.
PR
By Priya Raman · Science Reporter
Oct 5 08:00 ETSource: ClinicalTrials.gov
The wire
- 01NCT07859137, sponsored by Egypt's General Committee of Teaching Hospitals and Institutes, is not yet recruiting, with a start listed for October 2026 in patients with BMI 60 kg/m² or higher.
- 02GLP-1 drugs are already used before bariatric surgery in routine practice without trial evidence; the 2024 IFSO consensus agreed unanimously that evidence is insufficient to recommend routine preoperative medication.
- 03Registration only; no results. The listing notes adjacent trials PreMO (NCT06721507, 50 patients, tirzepatide) and NCT07622992 are unblinded and do not enroll BMI 60 and above.
From the source
Read at clinicaltrials.govSemaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher
NCT07859137 · PHASE4 · NOT YET RECRUITING · Sponsor: General Committee of Teaching Hospitals and Institutes, Egypt · Conditions: Morbid Obesity.
Source URL https://clinicaltrials.gov/study/NCT07859137
